--- a
+++ b/clusters/9knumclustersv2/clust_1379.txt
@@ -0,0 +1,99 @@
+From the projected start of scheduled study treatment, the following time periods must have elapsed:  half-lives from investigational agents,  weeks from cytotoxic therapy (except  days for temozolomide and  weeks from nitrosoureas),  weeks from antibodies, or  weeks (or  half-lives, whichever is shorter) from other systemic anti-tumor therapies; treatment on study may start one day after discontinuation of the optune device
+Use of any potent CYPA inhibitors or inducers within  days or  half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.
+Prior treatment with systemic immunotherapeutic agents within  weeks or  half-lives of the drug, whichever is shorter, before first infusion
+Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within  weeks or  half-lives of the drug, whichever is shorter, prior to first BFCRA infusion
+Any investigational drug therapy within  half-lives of the previous investigational study drug or  days, whichever is shorter.
+Received treatment, within  days or  half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade  or baseline
+Less than or equal to  half lives or  weeks, whichever is shorter, from the use of any investigational therapy prior to registration
+Patients who have had tyrosine kinase inhibitor therapy (e.g.: ibrutinib or idelalisib) within  half lives (or  days, whichever is shorter) of initiation of DMF
+Use of any approved tyrosine kinase inhibitors within  weeks or  half-lives of the agent, whichever is shorter, prior to study registration
+No other systemic therapies for prostate cancer within  days or  half-lives, whichever is shorter, prior to day  of study therapy
+Patients who are receiving any other investigational agents within  weeks or  half-lives (whichever is later) prior to the first dose of the study regimen
+Participation in an investigational therapeutic study within  weeks or within  drug half-lives (t/) prior to first dose, whichever time is greater
+Discontinuation of previous cancer therapies at least three () weeks or  half-lives, whichever is shorter.
+At least  weeks or  half-lives, whichever is shorter, should have elapsed since prior treatment as long as the patient recovered from any related toxicities to ? Grade .
+Received any other investigational agents within  weeks prior to enrollment, or <  half-lives since completion of previous investigational therapy, whichever is shorter
+Patients who have received prior systemic anti-cancer treatment within  weeks or  half-lives of prior to starting study treatment, whichever is shorter
+Treatment with systemic corticosteroids or other systemic immunosuppressive medications within past  weeks or  half-lives whichever is shorter
+Prior systemic cancer-directed treatments or investigational modalities ?  half lives or  weeks prior to starting CC-, whichever is shorter.
+Treatment with a monoclonal antibody within  days or  half-lives, whichever is shorter, from treatment with first dose of study drug
+From the projected start of scheduled study treatment, the following time periods must have elapsed:  half-lives from any investigational agent,  weeks from cytotoxic therapy (except  days for temozolomide and  weeks from nitrosoureas),  weeks from antibodies, or  weeks (or  half-lives, whichever is shorter) from other anti-tumor therapies.
+Patients who have had other investigational agents within  weeks or  half-lives, whichever is shorter, of the study enrollment
+Has received a prior monoclonal antibody within  weeks or  half-lives (whichever is shorter) before administration of study drug.
+From the projected start of scheduled study treatment, the following time periods must have elapsed:  half-lives from any investigational agent,  weeks from cytotoxic therapy (except  days for temozolomide and  weeks from nitrosoureas),  weeks from antibodies, or  weeks (or  half-lives, whichever is shorter) from other anti-tumor therapies
+Patient has had any treatment specific for tumor control within  weeks of dosing, or for investigational drugs and cytotoxic agents, within  half-lives or  weeks, whichever is shorter
+Patients who are receiving any other investigational agents. Patients who have taken an investigational drug within  days or  half-lives (minimum  days), whichever is shorter, prior to registration.
+Treatment with systemic corticosteroids or other systemic immunosuppressive medications within past  weeks or  half-lives whichever is shorter
+Patients who have received other investigational medication within the last  weeks or a period of its  half-lives (whichever is shorter) before the first OBP- administration.
+Previous (within  drug half-lives - if drug half-life in subjects is known - or  days, whichever is shorter, before the start of study treatment) or concomitant participation in another clinical study with investigational medicinal product(s) (IMP[s])
+From registration, the following time periods must have elapsed:  half-lives from any investigational agent,  weeks from cytotoxic therapy (except  days for temozolomide and  weeks from nitrosoureas),  weeks from antibodies, or  weeks (or  half-lives, whichever is shorter) from other anti-tumor therapies (including vaccines); no wash-out period required from time to treatment failure (TTF)
+Prior chemotherapy within  days or  half-lives (whichever is shorter) before starting treatment
+Prior therapy with investigational agent within  days or  half-lives (whichever is shorter) before starting treatment
+Participation in an investigational therapeutic study within  weeks or within  drug half-lives (t/) prior to first dose, whichever time is greater
+Any investigational or anti-tumour treatment within  weeks or  half-life period (whichever is shorter)prior to the initial administration of BI .
+Patients who were receiving prior therapy will require wash out period of either more than  weeks or more than  half-lives whichever shorter
+Anti-cancer therapy, such as chemotherapy, immunotherapy, targeted, and hormonal/endocrine therapy, or investigational agents within five half-lives or four weeks, whichever is shorter, prior to administration of the first dose of study drug (five half-lives or two weeks, whichever is shorter, for orally administered drugs and six weeks for nitrosoureas, mitomycin C, or bevacizumab)
+Use of investigational products or other anti-leukemic therapy within  half-lives or within  days prior to UCART administration whichever has a shorter duration
+Patients must be at least  weeks or  half-lives (whichever is shorter) from the last dose of prior investigational anti-cancer drugs.
+Treatment with any of the following anti-cancer therapies prior to the first dose of BGJ within the stated timeframes: \r\n* Cyclical chemotherapy (intravenous) within a period of time that is shorter than the cycle length used for that treatment (e.g.,  weeks for nitrosourea, mitomycin-C)\r\n* Biological therapy (e.g., antibodies - including bevacizumab) within a period of time that is =<  half-lives or =<  weeks, whichever is shorter, prior to starting study drug\r\n* Continuous or intermittent small molecule therapeutics within a period of time that is =<  half-lives or =<  weeks (whichever is shorter) prior to starting study drug\r\n* Any other investigational agents within a period of time that is =<  half-lives or less than \tthe cycle length used for that treatment or =<  weeks (whichever is shortest) prior to starting study drug\r\n* Wide field radiotherapy (including therapeutic radioisotopes such as strontium ) =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug
+Patients who have received an investigational anti-cancer drug within two weeks (or five half-lives, whichever is shorter) of LY administration
+Patients may not have received any other investigational agents within  weeks or  half lifes prior to registration, whichever is shorter
+At least  half-lives from time of last dose of anti-tumor directed antibody therapy or  days, whichever is shorter
+Patients who have completed previous systemic therapies  drug half-lives or -weeks prior to enrollment on study, whichever is shorter; Note: patients with anaplastic thyroid will be waived from this inclusion criteria
+Patients who are receiving any other investigational agents; patients who have taken an investigational drug within  days or  half-lives (minimum  days), whichever is shorter, prior to randomization
+Use of any potent CYPA inhibitors or inducers within  days or  half-lives (whichever is shorter) before the first dose of study drug.
+Have had prior systemic chemotherapy treatments or investigational modalities ?  half-lives or  weeks, whichever is shorter, prior to starting treatment with Andes- or who have not recovered from side effects, grade  or greater, of such therapy (except alopecia)
+Use of any investigational agents within  days or  half-lives (whichever is shorter) of study treatment.
+Receiving any other investigational agents within  days or  half-lives (whichever is shorter) prior to the first dose of study drug
+Patients must not have received an investigational agent within  weeks or ?  half lives, whichever is shorter, prior to starting study treatment
+At least  weeks or  half-lives, whichever is shorter, must have elapsed from the use of any anti-cancer therapy prior to randomization
+The subject has received any other type of investigational agent within  days or  half-lives, whichever is shorter, before the first dose of study treatment
+From the projected start of scheduled study treatment, the following time periods must have elapsed:\r\n*  weeks or  half-lives (whichever is shorter) from any investigational agent;\r\n*  weeks from cytotoxic therapy (except  days for temozolomide;  weeks from nitrosoureas);\r\n*  weeks from antibodies;\r\n*  weeks or  half-lives (whichever is shorter) from other anti-tumor therapies.\r\n*  days from Novo-Tumor Treating Fields (TTF)
+Subjects who have received an investigational agent within  days OR within  half-lives of the investigational agent (whichever is shorter) prior to the possible enrollment date on this study
+Chemotherapy within  days or at least  half-lives (whichever is shorter) prior to the planned start of study treatment.
+Prior systemic cancer-directed treatments or investigational modalities ?  half lives or  weeks, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy.
+Has received a prior monoclonal antibody within  weeks or  half-lives (whichever is shorter) before administration of study drug.
+Use of a study drug ? days or  half-lives, whichever is shorter.
+Prior systemic cancer-directed treatments or investigational modalities =<  half-lives or  weeks, whichever is shorter, prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)
+Use of an investigational drug within  days or within  half-lives of the investigational drug, whichever is shorter
+Prior systemic cancer-directed treatments or investigational modalities ?  half lives or  weeks whichever is shorter.
+Treatment with any investigational drug within  weeks or  half-lives, whichever is shorter, prior to the first dose of study medication
+Prior systemic cancer-directed treatments or investigational modalities =<  half-lives or  weeks, whichever is shorter, prior to starting study treatment
+From the projected start of scheduled study treatment, the following time periods must have elapsed:  half-lives from any investigational agent,  weeks from cytotoxic therapy (except  days for temozolomide and  weeks from nitrosoureas),  weeks from antibodies, or  weeks (or  half-lives, whichever is shorter) from other anti-tumor therapies
+Use of any approved tyrosine kinase inhibitors or investigational agents within  weeks or  half-lives of the agent, whichever is shorter, prior to receiving study drugs
+Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past  weeks (or five half-lives whichever is shorter; with a minimum of  days from the last dose)
+PART B: No previous treatment with a standard or investigational anti-cancer agent within predicted  half-lives of the agent; or  days whichever is the shorter; if the plasma half-life is not known or the previous therapy was a monoclonal antibody then a  day washout period will be considered as the default requirement
+Participation in an investigational therapeutic study within  weeks or within  drug half-lives (t/) prior to first dose, whichever time is greater
+Any use of an investigational drug within  days or  half-lives (whichever is shorter) prior to the first dose of BVD-.
+Concurrent investigational agents for non-malignant disease or prior investigational agents for non-malignant disease within  weeks or  half-lives (whichever is shorter) prior to day 
+Unable or unwilling to discontinue use of prohibited medications for at least  days or five half-lives of a drug (whichever is shorter) prior to the first dose of study drug and for the duration of the study
+Prior cancer-directed modalities or investigational drugs within  wks or  half lives, whichever is shorter
+Use of any potent cytochrome P A inhibitors or inducers within  days or  half-lives (whichever is shorter) before the first dose of study drug.
+Prior treatment anti-cancer therapy or use of any investigational agent within the past  days or  half-lives, whichever is shorter;
+Chemotherapy within  days or at least  half-lives (whichever is shorter) prior to the planned state of study treatment.
+Patients who are receiving any other investigational agents within  days or  effective half-lives (whichever is shorter) prior to first (st) dose of ibrutinib
+Chemotherapy within  days or at least  half-lives (whichever is shorter) prior to first dose of study treatment.
+Chemotherapy within  days or at least  half-lives (whichever is shorter) prior to the planned start of study treatment.
+Cancer-directed therapy (chemotherapy, radiotherapy) within  days of the first dose of study drug or  half-lives, whichever is shorter.
+Use of a study drug ? days or  half-lives (whichever is shorter) prior to the first dose of AZD
+Treatment with an investigational drug within the past  days or  half-lives of that drug, whichever is shorter.
+Any cancer-directed therapy within  days or  half-lives, whichever is shorter
+Any concurrent or prior use of an investigational drug (including MEK inhibitors) within previous  days or  half-lives, whichever is shorter
+Have received prior systemic anti-cancer therapy or investigational therapy within  weeks or five half-lives, whichever is shorter, prior to the first administration of study drug
+Prior systemic cancer-directed treatments or investigational modalities =<  half lives or  weeks, whichever is shorter, prior to starting study drug or who have not recovered from grade  or higher side effects of such therapy (except alopecia); an exception to this would be in patients receiving trastuzumab or pertuzumab immediately prior to trial enrollment, for whom the initial doses of trastuzumab and/or pertuzumab on study can be given within a time frame consistent with clinical guidelines and investigator discretion
+Another investigational therapy within  days or  half lives of randomization/enrollment, whichever is shorter.
+Taken an investigational drug within  days or  half-lives (minimum  days), whichever is shorter, prior to Study Day  (Parts  and ) or randomization (Part ).
+Subject who has received strong inhibitors or inducers of CYPA, A, D, or C within  days or five half-lives (whichever is shorter) prior to the first dose of veliparib (applicable to Part  only).
+Participation in an investigational therapeutic study within three weeks or within five drug half-lives (t/) prior to first dose, whichever time is greater (unless enrolling after progression on CMAP compassionate use carfilzomib protocol)
+Any anti-cancer drug therapy within  weeks ( weeks for mitomycin C or nitrosoureas) or  half-lives of the drug prior to study treatment, whichever is shorter, prior to study treatment.
+Prior treatment with cytokines is allowed provided that at least  weeks or  half-lives of the drug, whichever is shorter, have elapsed between the last dose and the proposed Cycle , Day 
+Received an investigational anti-cancer drug within  weeks or  half-lives (whichever is shorter) of study drug administration--- at least  days must have passed between the last dose of prior investigational anti-cancer drug and the first dose of study drug.
+Subject has received investigational therapy within  days or  half-lives, whichever is shorter, prior to the first dose of study drug.
+Received an investigational drug within  days or  half-lives, whichever is shorter, of the first scheduled dose of MEDI or not recovered from associated toxicities.
+Have received prior systemic anti-cancer therapy (including abiraterone) or investigational therapy within  weeks or five half-lives, whichever is shorter, prior to the first administration of study drug
+Treatment with other non-cytotoxic agents for NSCLC in the preceding ten days or four terminal half-lives, whichever is shorter
+Prior systemic cancer-directed treatments or investigational modalities ?  half lives or  weeks prior to starting study drugs, whichever is shorter.
+Chemotherapy within  days or at least  half-lives (whichever is shorter) prior to first dose of study treatment.
+ weeks or  half-lives since prior antibody-based therapy, whichever is shorter
+Prior systemic cancer-directed treatments or investigational modalities ?  half lives or  weeks prior to starting CC-, whichever is shorter. Hydroxyurea is allowed to control peripheral leukemia blasts.
+Systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents) or investigational device within  weeks or  half-lives (if the drug's half-life in subject is known) prior to randomization, whichever is shorter